Vascular Dementia (VaD) is one of the most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. Vascular Dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic Vascular Dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances. The way by which Vascular Dementia affects people varies depending on the different underlying causes and more generally from person to person. Symptoms may develop suddenly, for example after a stroke, or more gradually, such as with small vessel disease. In practical terms, the diagnosis of Vascular Dementia should be suspected in patients with significant vascular risk factors, stroke, or heart disease who exhibit abrupt changes in cognition. There is currently no cure for Vascular Dementia: the brain damage that causes it cannot be reversed.
DelveInsight’s, “Vascular Dementia Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for free sample report: https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight
Some of Vascular Dementia Companies are:
DelveInsight’s Vascular Dementia report covers around 10+ products under different phases of clinical development like:
Some of Vascular Dementia Therapies are:
Current Vascular Dementia Treatment Scenario and Vascular Dementia Emerging Therapies:
Table of Contents:
Introduction
Executive Summary
Vascular Dementia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Vascular Dementia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vascular Dementia Collaboration Deals
Late Stage Products (Phase III)
Akatinol Memantine: Merz Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BAC: Charsire Pharmaceutical
Early Stage Products (Phase I)
AR1001: AriBio
Inactive Products
Vascular Dementia Key Companies
Vascular Dementia Key Products
Vascular Dementia- Unmet Needs
Vascular Dementia- Market Drivers and Barriers
Vascular Dementia- Future Perspectives and Conclusion
Vascular Dementia Analyst Views
Appendix
Request for Deatiled TOC: https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/vascular-dementia-pipeline-insight